Dm Disease-A-Month最新文献

{"title":"Information for Readers","authors":"","doi":"10.1016/S0011-5029(25)00041-0","DOIUrl":"10.1016/S0011-5029(25)00041-0","url":null,"abstract":"","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 4","pages":"Article 101891"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C2: Editorial Board","authors":"","doi":"10.1016/S0011-5029(25)00039-2","DOIUrl":"10.1016/S0011-5029(25)00039-2","url":null,"abstract":"","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 4","pages":"Article 101889"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Foreword: Diabetic Kidney Disease","authors":"Jerrold B. Leikin MD FACOEM, FACP, FACEP, FACMT, FAACT, FASAM (Editor in Chief- Disease-A-Month)","doi":"10.1016/j.disamonth.2024.101847","DOIUrl":"10.1016/j.disamonth.2024.101847","url":null,"abstract":"","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 4","pages":"Article 101847"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetic Kidney Disease","authors":"Anna Gaddy MD ,&nbsp;Mohamed Elrggal MD ,&nbsp;Hector Madariaga MD ,&nbsp;Adam Kelly MD ,&nbsp;Edgar Lerma MD ,&nbsp;Gates B Colbert MD","doi":"10.1016/j.disamonth.2024.101848","DOIUrl":"10.1016/j.disamonth.2024.101848","url":null,"abstract":"<div><div>Diabetic kidney disease is a leading cause of kidney failure worldwide and is easily detectable with screening examination. Diabetes causes hyperfiltration and activation of the renin-angiotensin aldosterone system by hemodynamic changes within the nephron, which perpetuates damaging physiology. Diagnosis is often clinical after detection of heavy proteinuria in a patient with diabetes,but can be confirmed by observation of histologic stages on kidney biopsy. Mainstays of treatment include angiotensin conversion or receptor blockade, mineralocorticoid receptor blockade, and tight glucose control. Newer agents favored in diabetic kidney disease are sodium glucose-cotransporters and glucagon-like peptide 1 receptor agonists, both for glycemic control and for various methods of reversing damaging physiology.</div></div>","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 4","pages":"Article 101848"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S0011-5029(25)00040-9","DOIUrl":"10.1016/S0011-5029(25)00040-9","url":null,"abstract":"","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 4","pages":"Article 101890"},"PeriodicalIF":3.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The integration of artificial intelligence into clinical medicine: Trends, challenges, and future directions","authors":"Prasanna Sakthi Aravazhi MBBS ,&nbsp;Praveen Gunasekaran MBBS ,&nbsp;Neo Zhong Yi Benjamin MBBS ,&nbsp;Andy Thai MD ,&nbsp;Kiran Kishor Chandrasekar MBBS ,&nbsp;Nikhil Deep Kolanu MBBS ,&nbsp;Priyadarshi Prajjwal MBBS ,&nbsp;Yogesh Tekuru MBBS ,&nbsp;Lissette Villacreses Brito MD ,&nbsp;Pugazhendi Inban MD","doi":"10.1016/j.disamonth.2025.101882","DOIUrl":"10.1016/j.disamonth.2025.101882","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background and Objectives&lt;/h3&gt;&lt;div&gt;AI has emerged as a transformative force in clinical medicine, changing the diagnosis, treatment, and management of patients. Tools have been derived for working with ML, DL, and NLP algorithms to analyze large complex medical datasets with unprecedented accuracy and speed, thereby improving diagnostic precision, treatment personalization, and patient care outcomes. For example, CNNs have dramatically improved the accuracy of medical imaging diagnoses, and NLP algorithms have greatly helped extract insights from unstructured data, including EHRs. However, there are still numerous challenges that face AI integration into clinical workflows, including data privacy, algorithmic bias, ethical dilemmas, and problems with the interpretability of “black-box” AI models. These barriers have thus far prevented the widespread application of AI in health care, and its possible trends, obstacles, and future implications are necessary to be systematically explored. The purpose of this paper is, therefore, to assess the current trends in AI applications in clinical medicine, identify those obstacles that are hindering adoption, and identify possible future directions. This research hopes to synthesize evidence from other peer-reviewed articles to provide a more comprehensive understanding of the role that AI plays to advance clinical practices, improve patient outcomes, or enhance decision-making.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A systematic review was done according to the PRISMA guidelines to explore the integration of Artificial Intelligence in clinical medicine, including trends, challenges, and future directions. PubMed, Cochrane Library, Web of Science, and Scopus databases were searched for peer-reviewed articles from 2014 to 2024 with keywords such as “Artificial Intelligence in Medicine,” “AI in Clinical Practice,” “Machine Learning in Healthcare,” and “Ethical Implications of AI in Medicine.” Studies focusing on AI application in diagnostics, treatment planning, and patient care reporting measurable clinical outcomes were included. Non-clinical AI applications and articles published before 2014 were excluded. Selected studies were screened for relevance, and then their quality was critically appraised to synthesize data reliably and rigorously.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;This systematic review includes the findings of 8 studies that pointed out the transformational role of AI in clinical medicine. AI tools, such as CNNs, had diagnostic accuracy more than the traditional methods, particularly in radiology and pathology. Predictive models efficiently supported risk stratification, early disease detection, and personalized medicine. Despite these improvements, significant hurdles, including data privacy, algorithmic bias, and resistance from clinicians regarding the “black-box” nature of AI, had yet to be surmounted. XAI has emerged as an attractive solution that offers the promise to enhance int","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 6","pages":"Article 101882"},"PeriodicalIF":3.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forword: The integration of artificial intelligence into clinical medicine: Trends, challenges, and future directions","authors":"Jerrold B. Leikin MD FACOEM, FACP, FACEP, FACMT, FAACT, FASAM (Editor in Chief - Disease-A-Month)","doi":"10.1016/j.disamonth.2025.101881","DOIUrl":"10.1016/j.disamonth.2025.101881","url":null,"abstract":"","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 6","pages":"Article 101881"},"PeriodicalIF":3.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug","authors":"Andrew M. Farrar Ph.D. ,&nbsp;Isabelle H. Nordstrom ,&nbsp;Kaitlyn Shelley B.S. ,&nbsp;Gayane Archer M.D. ,&nbsp;Kaitlyn N. Kunstman M.D. ,&nbsp;Joseph J. Palamar Ph.D.","doi":"10.1016/j.disamonth.2024.101851","DOIUrl":"10.1016/j.disamonth.2024.101851","url":null,"abstract":"<div><div>3,4-methylenedioxymethamphetamine (MDMA; commonly referred to as “ecstasy” or “molly”) is a substituted amphetamine drug that is used recreationally for its acute psychoactive effects, including euphoria and increased energy, as well as prosocial effects such as increased empathy and feelings of closeness with others. Acute adverse effects can include hyperthermia, dehydration, bruxism, and diaphoresis. Post-intoxication phenomena may include insomnia, anhedonia, anxiety, depression, and memory impairment, which can persist for days following drug cessation. MDMA acts as a releasing agent for monoamine neurotransmitters, including dopamine (DA), norepinephrine (NE) and serotonin (5-HT), by interfering with vesicular storage and transporter function, thus increasing extracellular levels of DA, NE, and 5-HT. Medical intervention in response to adverse events is complicated by the fact that illicitly-acquired MDMA is frequently adulterated, contaminated, or outright replaced with other psychoactive drugs such as synthetic cathinones (“bath salts”) or methamphetamine, often unknown to the person using the drug. This review provides background on the legal status of MDMA and its use patterns, including proposals for its use as an adjunct in psychotherapy. It also discusses the pharmacological properties, mental and physical health effects, and interactions of MDMA with other drugs, with special focus on harm reduction strategies. This information will help healthcare providers assess adverse health effects related to MDMA/ecstasy use in order to facilitate appropriate treatment strategies and improve patient outcomes.</div></div>","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 3","pages":"Article 101851"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Foreword: Hallucinogenic amphetamine, cannabis and opioid issues for the primary care practitioner","authors":"Jerrold B. Leikin MD FACOEM, FACP, FACEP, FACMT, FAACT, FASAM (Editor in Chief - Disease-A-Month)","doi":"10.1016/j.disamonth.2025.101852","DOIUrl":"10.1016/j.disamonth.2025.101852","url":null,"abstract":"","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 3","pages":"Article 101852"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C2: Editorial Board","authors":"","doi":"10.1016/S0011-5029(25)00023-9","DOIUrl":"10.1016/S0011-5029(25)00023-9","url":null,"abstract":"","PeriodicalId":51017,"journal":{"name":"Dm Disease-A-Month","volume":"71 3","pages":"Article 101874"},"PeriodicalIF":3.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}